Swiss National Bank
ITOS

Swiss National Bank’s iTeos Therapeutics ITOS Stock Holding History

Swiss National Bank’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-40,100
Closed -$409K – 2458
2024
Q3 		$409K Sell
40,100
-5,800
-13% -$88.5K ﹤0.01% 2454
2024
Q2 		$681K Hold
45,900
– – ﹤0.01% 2337
2024
Q1 		$626K Hold
45,900
– – ﹤0.01% 2408
2023
Q4 		$503K Sell
45,900
-4,700
-9% -$46.6K ﹤0.01% 2475
2023
Q3 		$554K Hold
50,600
– – ﹤0.01% 2484
2023
Q2 		$670K Buy
50,600
+8,400
+20% +$120K ﹤0.01% 2479
2023
Q1 		$574K Sell
42,200
-5,000
-11% -$89.6K ﹤0.01% 2492
2022
Q4 		$922K Buy
47,200
+1,400
+3% +$27.4K ﹤0.01% 2387
2022
Q3 		$872K Hold
45,800
– – ﹤0.01% 2399
2022
Q2 		$943K Buy
45,800
+12,400
+37% +$294K ﹤0.01% 2399
2022
Q1 		$1.07M Buy
33,400
+2,400
+8% +$87.2K ﹤0.01% 2373
2021
Q4 		$1.44M Buy
+31,000
New +$1.03M ﹤0.01% 2255
2021
Q2 		– Sell
-27,700
Closed -$947K – 2649
2021
Q1 		$947K Hold
27,700
– – ﹤0.01% 2362
2020
Q4 		$937K Buy
+27,700
New +$733K ﹤0.01% 2321

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Swiss National Bank's ITOS Position: Q4 2024 in Review

Swiss National Bank sold out of iTeos Therapeutics (ITOS) in Q4 2024, closing a stake of 40,100 shares — an estimated $409K sold.

Swiss National Bank first reported a position in ITOS in Q4 2020 and held it in 14 quarters. The position peaked at $1.44M in Q4 2021. 137 funds tracked by Wall St. Rank hold ITOS as of Q4 2024.

  • Swiss National Bank reported no remaining iTeos Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Swiss National Bank sold 40,100 iTeos Therapeutics shares in Q4 2024, an estimated $409K.
  • Swiss National Bank first reported a position in iTeos Therapeutics in Q4 2020 and held it in 14 quarters.
  • Swiss National Bank's iTeos Therapeutics position peaked at $1.44M in Q4 2021.
  • 137 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2024.

Based on Swiss National Bank's 13F filing for Q4 2024, filed 10 Feb 2025.